Quasimodo, thank you for the message and great questions.
The R&D expense decrease is a positive sign that the company is conserving cash to make more focused bets. I don't have info on where it cut.
They have a cancer drug in phase III trial, early results were positive, the trial is ongoing, likely to have more positive results in the next couple months.
Option size and strike price are reasonable. I don't know much about the leases.
I will never be able to drill down all the details on any single stock so I am making diversified bets on many under valued stocks. My large holdings are ALVR, AIRN, EONC PCYC and DUSA. PCYC is the only stock I am buying at current price, today got 3000 shares @4.51, there were about 7 100-share lots sold to me, very smaller sellers, maybe small guys finally giving up shares bought at $30-50 years ago. I am buying more at the lower price bound (currently 4.51), never chase it since it will run up fast on small buy order. |
